PIMS-TS in Intensive Care: Retrospective Cohort Trial

Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) in Pediatric Intensive Care: Retrospective Cohort Trial

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05388396

Acronym

PIMS-TS INT

Enrollment

180

Registered

2022-05-24

Start date

2022-08-01

Completion date

2023-01-30

Last updated

2023-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pims-Ts

Keywords

PIMS-TS, children, child, intensive care, critical illness

Brief summary

Pediatric Multisystem Inflammatory Syndrome Temporally associated with SARS-CoV-2, (PMIS-TS) represents the new unit, partially imitating the previously described Kawasaki disease. Due to variable and frequently incomplete clinical presentation together with variable disease severity, the real incidence in pediatric population remains unclear. Currently, PIMS-TS is defined by persistent fever, elevation of inflammatory markers, organ dysfunction (cardiac, central nervous system, respiratory, coagulation, renal, gastrointestinal), skin lesions (exanthematous), and absence of other possible etiology.

Detailed description

During the world COVID-19 pandemic (2020-2022), pediatric patients with PIMS-TS represented a significant part of pediatric intensive care unit (PICU) load. The initial clinical presentation of patients with PIMS-TS could vary significantly, and also due to progressively evolving recommendations, the diagnostic a therapy could vary regionally and over the time too. The aim of this retrospective cohort trial was to describe the initial clinical presentation, diagnostics, therapy and clinical outcome of pediatric patients admitted during 2020-2022 to the one of the 3 university hospital PICUs.

Interventions

OTHERPIMS-TS diagnostic a treatment

PIMS-TS diagnostic a treatment

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 19 Years

Inclusion criteria

* pediatric patients with PIMS-TS * PICU admission

Exclusion criteria

* insufficient data * patients not admitted to PICU

Design outcomes

Primary

Measure	Time frame	Description
Initial clinical presentation	During the first 24 hours after PICU admission	Vital signs
Initial laboratory results	During the first 24 hours after PICU admission	—
PIMS-TS treatment	During the first month after PICU admission	PIMS-TS treatment specification

Secondary

Measure	Time frame	Description
PIMS-TS outcome	after one month from hospital discharge	clinical and cardiology outcome after 1 month

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026